<DOC>
	<DOCNO>NCT01374373</DOCNO>
	<brief_summary>The purpose study assess safety efficacy weekly epoetin alfa ( Hemax® ) administer 12 week patient non curable solid tumor lymphoma anemia ( hemoglobin &lt; 10g/dl ) undergo palliative care chemotherapy .</brief_summary>
	<brief_title>Epoetin Alfa ( Hemax® ) Phase IV Study Chemotherapy Induced Anemia</brief_title>
	<detailed_description>Patients non curable solid tumor lymphoma anemia ( hemoglobin &lt; 10g/dl ) undergo palliative care chemotherapy enter 12 week single arm open label study . Epoetin alfa 40.000-60.000 IU/week administer subcutaneously control every 2 week . Up titration perform accord currently approve prescription guidance total 12 week treatment . Study end point assess every 4 week final 12 week visit .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Confirmed diagnosis non curable cancer lymphoma Receiving palliative chemotherapy regimen Hemoglobin &lt; 10.0 g/dL Performance ≤ 3 Eastern Cooperative Oncology Group ( ECOG ) performance status Life expectancy ≥ 3 month Postmenopausal premenopausal woman receive effective contraceptive method Active bleeding may cause anemia prior 30 day . Uncontrolled hypertension Anemia another cause cancer chemotherapy Untreated iron folic acid deficiency Transfusion last 30 day prior baseline visit Treatment erythropoiesis stimulate agent 3 month prior baseline visit Increased risk thromboembolic disease Radiotherapy pelvis spine last 60 day Myelodysplasic syndrome History congestive heart failure Pregnant lactating Patient know allergy human albumin relate product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Chemotherapy</keyword>
	<keyword>Anemia</keyword>
	<keyword>Epoetin alfa</keyword>
	<keyword>Erythropoiesis stimulate agent ( ESA )</keyword>
</DOC>